title: The use of weighted and scored risk assessment models for venous thromboembolism.
abstract: Formalised risk assessment models (RAMs) for venous thromboembolism (VTE) using weighted and scored variables have only recently been widely incorporated into international antithrombotic guidelines. Scored and weighted VTE RAMs have advantages over a simplified group-specific VTE risk approach, with the potential to allow more tailored strategies for thromboprophylaxis and an improved estimation of the risk/benefit profile for a particular patient. The derivation of VTE RAMs should be based on variables that are  a priori  defined or identified in a univariate analysis and the predictive capability of each variable should be rigorously assessed for both clinical and statistical significance and internal consistency and completeness. The assessment of the RAM should include the goodness of fit of the model and construction of a prognostic index score. Any VTE RAM which has been derived must undergo validation of that model before it can be used in clinical practice. Validation of the model should be performed in a "deliberate" prospective fashion across several diverse clinical sites using pre-defined criteria using basic standards for performing model validation. We discuss the basic concepts in the derivation of recent scored and weighted VTE RAMs in hospitalised surgical and medical patients and cancer outpatients, the mechanisms for accurate external validation of the models, and implications for their use in clinical practice.
authors.affiliation: James P Wilmott Cancer Center, Department of Medicine, Division of Hematology/Oncology, University of Rochester Medical Center, Rochester, NY 14642, USA. Alex_Spyropoulos@URMC.Rochester.edu
authors.forename: Alex C
authors.initials: AC
authors.lastname: Spyropoulos
authors.forename: Thomas
authors.initials: T
authors.lastname: McGinn
authors.forename: Alok A
authors.initials: AA
authors.lastname: Khorana
mesh_terms: D005343:Fibrinolytic Agents / Q000627:therapeutic use; D006760:Hospitalization; D006801:Humans; D008955:Models, Cardiovascular; D009369:Neoplasms / Q000150:complications / Q000188:drug therapy; D018570:Risk Assessment / Q000379:methods / Q000706:statistics & numerical data; D012307:Risk Factors; D054556:Venous Thromboembolism / Q000453:epidemiology / Q000209:etiology* / Q000517:prevention & control
chemical_list: D005343:Fibrinolytic Agents